
Motus GI Holdings MOTS
Quarterly report 2024-Q1
added 05-16-2026
Motus GI Holdings EV - Enterprise Value 2011-2026 | MOTS
Annual EV - Enterprise Value Motus GI Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 568 K | 889 K | 10.6 M | 38.2 M | 44.7 M | 48.4 M | -3.29 M | 2.16 M | 5.44 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 48.4 M | -3.29 M | 16.4 M |
EV - Enterprise Value of other stocks in the Diagnostics research industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
-22.7 M | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
-19.1 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
851 M | - | - | $ 1.31 B | ||
|
DermTech
DMTK
|
70.4 M | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
22.9 B | $ 202.23 | -0.41 % | $ 22.4 B | ||
|
Celcuity
CELC
|
5.57 B | $ 86.81 | -1.96 % | $ 4.06 B | ||
|
Akumin
AKU
|
1.64 B | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
583 M | $ 18.71 | 0.16 % | $ 576 M | ||
|
Co-Diagnostics
CODX
|
-1.92 M | $ 3.88 | -9.56 % | $ 5.16 M | ||
|
Castle Biosciences
CSTL
|
463 M | $ 20.58 | -0.58 % | $ 597 M | ||
|
Aspira Women's Health
AWH
|
10.6 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
69.5 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
15 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
26.2 M | - | - | $ 562 M | ||
|
Guardant Health
GH
|
15.2 B | $ 130.26 | -1.03 % | $ 16.3 B | ||
|
CareDx, Inc
CDNA
|
1.04 B | $ 24.1 | 4.92 % | $ 1.28 B | ||
|
Chembio Diagnostics
CEMI
|
39.2 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-2 K | - | - | $ 9.42 M | ||
|
Interpace Biosciences
IDXG
|
16.3 M | $ 1.64 | 2.19 % | $ 7.26 M | ||
|
Illumina
ILMN
|
23.8 B | $ 164.64 | 2.28 % | $ 25.5 B | ||
|
ICON Public Limited Company
ICLR
|
16.5 B | $ 147.28 | 0.75 % | $ 11.6 B | ||
|
HTG Molecular Diagnostics
HTGM
|
3.16 M | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
-2.71 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
6.64 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.34 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
654 M | - | 0.12 % | $ 80.1 M | ||
|
Lantheus Holdings
LNTH
|
5.9 B | $ 104.72 | 0.19 % | $ 7.07 B | ||
|
Charles River Laboratories International
CRL
|
11.4 B | $ 190.02 | 1.34 % | $ 9.42 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
5.02 B | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
14 B | $ 465.86 | -0.32 % | $ 13.4 B | ||
|
Mettler-Toledo International
MTD
|
32.1 B | $ 1 152.77 | 1.88 % | $ 23.8 B | ||
|
Exact Sciences Corporation
EXAS
|
22 B | - | - | $ 19.8 B | ||
|
NeoGenomics
NEO
|
1.85 B | $ 11.11 | -0.36 % | $ 1.42 B | ||
|
National Research Corporation
NRC
|
432 M | $ 18.29 | -2.69 % | $ 409 M | ||
|
Myriad Genetics
MYGN
|
598 M | $ 4.33 | -0.12 % | $ 401 M | ||
|
Natera
NTRA
|
30.1 B | $ 214.63 | 1.2 % | $ 29.3 B | ||
|
Pacific Biosciences of California
PACB
|
1.21 B | $ 1.35 | 2.67 % | $ 405 M | ||
|
Personalis
PSNL
|
380 M | $ 10.05 | 4.8 % | $ 897 M | ||
|
Koninklijke Philips N.V.
PHG
|
43.5 B | $ 26.73 | 1.02 % | $ 25.3 B | ||
|
Senseonics Holdings
SENS
|
376 M | $ 7.27 | 1.25 % | $ 303 M | ||
|
QIAGEN N.V.
QGEN
|
11.3 B | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
2.13 B | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
6.63 M | $ 2.01 | -1.95 % | $ 4.62 M | ||
|
Twist Bioscience Corporation
TWST
|
1.55 B | $ 82.74 | 8.62 % | $ 4.95 B | ||
|
Laboratory Corporation of America Holdings
LH
|
33.1 B | $ 264.65 | -0.57 % | $ 22 B | ||
|
Thermo Fisher Scientific
TMO
|
186 B | $ 473.92 | 1.08 % | $ 179 B | ||
|
Trinity Biotech plc
TRIB
|
327 M | $ 0.68 | 3.86 % | $ 244 M | ||
|
Neogen Corporation
NEOG
|
2.26 B | $ 9.3 | 2.14 % | $ 2.02 B | ||
|
Invitae Corporation
NVTA
|
2.11 B | - | - | $ 21.2 M |